DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rnnss7/circulating_tumor) has announced the addition of the "Circulating Tumor Cells Market Analysis By Technology, By Application and Segment - Forecasts To 2020" report to their offering.
Global circulating tumor cells market is expected to reach USD 2.28 billion by 2020.
Tumor cell detection was the leading product segment in 2013 primarily owing to the advantages associated with therapeutic monitoring and high procedure prices. Its market is expected to reach an estimated value of over USD 250.0 million by 2020.
Growing prevalence of cancer has heightened the need for effective and early diagnosis. Circulating tumor cells cater to this heightened need, and are therefore expected to witness a surge in demand during the forecast period. Majority of cancer deaths are due to circulating tumor cells and an early diagnosis of the same is expected to increase survival rates. Targeted therapy in cancer has large untapped opportunities, and therefore entails extensive R&D investments aimed at new product development. However, high procedure costs and lack of commercialized products are expected to impede market growth during the forecast period.
For the purpose of this study, the report has segmented the global circulating tumor cells market on the basis of technology, application.
Global Circulating Tumor Cells Technology Outlook (Revenue, USD Million, 2012 - 2020)
- Tumor Cell Enrichment
- Immunological and Immunomagnetic
- Tumor Cell Detection
Global Circulating Tumor Cells Application Outlook (Revenue, USD Million, 2012 - 2020)
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Others (pancreatic, lung, ovarian cancer)
- AVIVA BioSciences Corporation
- AdnaGen AG
- Celula Inc
- Advanced Cell Diagnostics Inc.
- Epic Sciences Inc.
- Rarecells Inc.
- Fluxion Biosciences Inc
- Silicon Biosystems S.p.A
- Vitatex Inc
For more information visit http://www.researchandmarkets.com/research/rnnss7/circulating_tumor